Alto Neuroscience, which uses AI to identify biomarkers to develop targeted psychiatric therapy options, announced that it has closed a $25 million equity investment with new investor Alpha Wave Ventures and a $25 million investment from K2 HealthVentures. has entered into a credit facility of up to $35 million with
Series B brings extension round About 60 million dollars. The company will use the funds to continue enhancing its Precision Psychiatry platform, which evaluates brain biomarkers using wearable data, EEG activity, genetics, behavioral task performance and other factors to match patients with Alto medication. Is.
The funding also helps the company complete Phase II trials with four of its new drug candidates.
“We are diligent in advancing our pipeline of diverse product candidates and these investments exemplify our shared commitment to developing novel treatments for many mental health conditions,” Nick Smith, Alto Neuroscience’s chief financial officer, said in a statement. ” “This additional equity investment and flexible credit facility has enabled us to complete four definitive studies that, if successful, will enable future registration studies indicating high unmet medical need. We are pleased to work with K2 investors to advance Alto’s mission through critical validation points in the years to come.”
Tech-enabled cough monitoring company C-Mo Medical Solutions announced an expansion of its seed investment round to €4.8 million ($5.2 million), which will help the company further expand the cough assessment capabilities of its technology.
Boehringer Ingelheim Venture Fund led the round with participation from Portugal Ventures and High-Tech Grunderfonds. The recent expansion adds Novelis Biotech as a new investor.
“We are very pleased to support C-mo and join the investor consortium. We are impressed by the complementarity and dedication of the C-mo team that developed this innovative product. Translation of Clinically Relevant Symptoms [such as a] Cough is an objective, measurable marker currently missing in drug development or treatment, Kjell Mortier, fund manager at Novelis Biotech, said in a statement.
Sexual healthcare provider TBD Health announced a $4.4 million seed round that will help the company expand to all 50 states.
Tusk Venture Partners led the round with participation Human Ventures, Hyphen Capital, Expansion VC, Springdale Ventures, The Community Fund, Starbloom Capital and Strategic Angel Investors.
The Nevada-based company offers at-home STD testing, generic Plan-B contraceptives, and telemedicine appointments through its digital platform as well as an in-person clinic in Las Vegas.
TBD’s at-home testing services were previously only available to Nevada, Arizona, Washington, Massachusetts, Connecticut and Florida residents. The company said it will now be able to offer its services across the country after clearing clinical and regulatory hurdles.
“More and more we are seeing local sexual health clinics shuttering nationwide due to lack of funding and resources,” said Stephanie Estey, co-founder and co-CEO of TBD Health. This puts enormous pressure on those who need immediate care. is needed.” Statement. “We want to be a solution for those living in the sexual health care desert and beyond by offering a more accessible and acceptable way to take care of your sexual health.”
